Upcoming Data Presentations for BRIUMVI®
TG Therapeutics, Inc. (NASDAQ: TGTX), proudly announces an exciting schedule showcasing BRIUMVI® (ublituximab-xiiy) data for relapsing forms of multiple sclerosis (RMS). This information will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting taking place in Barcelona.
Presentation Highlights
The event will span three days, from September 24 to 26. Renowned experts will share findings pertaining to the efficacy and safety of BRIUMVI® in managing RMS.
Key Presentations Scheduled
Oral Presentation Details
One of the key presentations titled "Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label Extension" is set for September 24. It will occur at 14:55 CEST, offering insights into six years of research data.
- Session: Therapeutic Interventions - Lecture Hall 117
- Abstract Number: ECTRIMS25-1571
- Lead Author: Dr. Bruce Cree from the Weill Institute for Neurosciences, University of California
ePoster Presentations
Attendees can also look forward to several ePoster presentations, covering topics such as:
- Updates from the ENHANCE Study: This presentation focuses on the safety and tolerability of a modified ublituximab dosing regimen. It details the results from extensive clinical assessments.
- Real-World Experience from the ENABLE Study: Another ePoster highlights the clinical experience of patients commencing treatment with BRIUMVI®, showcasing real-world outcomes from a Phase 4 observational study.
About BRIUMVI® (ublituximab-xiiy)
BRIUMVI® represents an innovative approach in treating various autoimmune disorders, specifically targeting CD20-expressing B-cells. This monoclonal antibody's unique construction enhances its effectiveness in B-cell depletion, providing significant promise for RMS patients.
Current Indications
In the United States and Europe, BRIUMVI® holds approval for treating adult patients exhibiting active RMS. Its operational advantages lead to impressive clinical outcomes that resonate with healthcare professionals and patients alike.
Further Steps and Availability of Data
Post-presentation, comprehensive data will be accessible through the Publications page on TG Therapeutics' official website. This ensures ongoing transparency and information dissemination regarding BRIUMVI®.
Frequently Asked Questions
What is the focus of TG Therapeutics's upcoming presentations?
The presentations will highlight the efficacy and safety of BRIUMVI® in treating relapsing multiple sclerosis at the ECTRIMS annual meeting.
When is the presentation scheduled?
The main oral presentation will take place on September 24 at 14:55 CEST.
Where can I find the data post-presentation?
The data discussed will be available on the Publications page of TG Therapeutics’ website.
Who leads the oral presentation?
Dr. Bruce Cree, from the Weill Institute for Neurosciences, will lead the oral presentation.
What is BRIUMVI® used for?
BRIUMVI® is indicated for treating adult patients with active relapsing multiple sclerosis.
